ABAC Therapeutics develops targeted antibiotics that specifically combat severe bacterial infections resistant to standard treatments. By utilizing advanced drug design techniques, the company aims to improve patient outcomes and reduce the duration of hospital stays for affected individuals.

The startup develops immunomodulatory therapeutics that target autoimmunity and cancer by utilizing proprietary transcription data analysis to identify key immune system compartments. This approach enables healthcare professionals to tailor treatment plans for more effective patient outcomes.

Adcendo is developing a first‑in‑class antibody‑drug conjugate (ADC) that targets the uPARAP receptor, which is overexpressed on mesenchymal cancer cells such as soft‑tissue sarcoma. The ADC links a humanized anti‑uPARAP antibody to a microtubule‑disrupting payload via a cleavable linker, enabling tumor‑specific delivery and reduced systemic toxicity. ADCE‑D01 is in a Phase I/II trial with a companion diagnostic to select uPARAP‑positive patients.

Adcytherix is a clinical‑stage biopharma that creates next‑generation antibody‑drug conjugates (ADCs) by linking clinically validated antibodies to innovative payloads derived from already approved cancer drugs. Their platform uses advanced conjugation chemistry to improve stability, control payload release, and overcome resistance mechanisms, expanding the therapeutic window for high‑unmet‑need solid tumors. The company’s pipeline targets cancers that are refractory to existing ADCs, offering more precise and tolerable oncology therapies.

Adicet Bio develops allogeneic gamma delta CAR T cell therapies to target and eliminate cancer cells, utilizing the unique properties of gamma delta T cells for enhanced tissue homing and drug exposure. This approach addresses the need for effective, on-demand immunotherapies in the treatment of cancer and autoimmune diseases.

Agomab is developing small molecule inhibitors targeting ALK5 (TGFβ1R) to treat fibrotic diseases, including fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis. Their therapies aim to maintain and restore organ function by modulating growth factor biology in affected tissues.

Anaveon is developing IL-2 complexes, specifically ANV419 and ANV600, which enhance effector T cell functions to improve immune responses in cancer treatment. The company addresses the need for safe and effective immunotherapies for patients with high unmet medical needs by utilizing protein engineering to optimize cytokine activity.

Antios Therapeutics is a clinical-stage biopharmaceutical company focused on developing an oral drug candidate aimed at providing a potentially curative treatment for hepatitis B virus (HBV) infections. The company leverages its experienced leadership team to advance therapies that address the significant unmet medical need for effective HBV management.

CytoReason develops a cell-centered computational model that analyzes biological data to map disease mechanisms and treatment effects. This technology enables pharmaceutical companies to prioritize drug development and make data-driven decisions by providing insights into drug performance across diverse patient populations.

Elevation develops high voltage power management solutions, including AC-DC controllers, to enhance energy efficiency in industrial applications. Their technology reduces energy losses and operational costs for manufacturers by improving power conversion and management processes.

Eloxx Pharmaceuticals develops small molecule RNA-modulating therapies that target premature stop codon mutations, which disrupt protein synthesis in over 1,800 rare and ultra-rare diseases. Their lead candidate, ELX-02, aims to restore full-length protein production in conditions such as cystic fibrosis and cystinosis, addressing the critical lack of functional proteins in affected patients.

Emergence is a biopharmaceutical company developing antibody-drug conjugates (ADCs) that target specific cancer cells, aiming to improve treatment outcomes for cancers with significant unmet medical needs. Their approach enhances the precision of cancer therapies, reducing systemic toxicity while increasing efficacy for patients facing aggressive malignancies.

Enlivex develops Allocetra™, an off‑the‑shelf allogeneic cell therapy that reprograms macrophages to a homeostatic, anti‑inflammatory state, delivering significant pain reduction and functional improvement for patients with age‑related knee osteoarthritis. The therapy is manufactured as a cryopreserved product for rapid intravenous or intra‑articular administration and is supported by Phase II data showing a favorable safety profile in over 250 patients. Enlivex also backs its corporate treasury with a fee‑linked exposure to the Rain prediction‑markets protocol, aligning shareholder value with network activity.

GraftSolutions develops surgical devices that improve coronary artery bypass grafting outcomes. Its VIOLA™ system enables clam‑less proximal aortic anastomosis, eliminating the need for aortic clamps and reducing stroke and delirium risk, while the VEST™ external sleeve reinforces saphenous vein grafts to lower intimal hyperplasia and re‑vascularization rates. Both products are clinically validated and aim to extend graft durability and lower overall care costs for cardiac surgery programs.

HARM provides an AI-powered platform for individuals experiencing harm to quickly access immediate, trusted support. The system intelligently identifies the nature of the reported harm and routes users directly to appropriate, city-approved advocacy, legal, or housing resources. This streamlined process eliminates confusion while generating de-identified data insights to help municipal leaders optimize community support services.

Imel Biotherapeutics is developing a mitochondrial replacement therapy that enhances T cell functionality by replacing dysfunctional mitochondria with healthy ones, achieving over 90% mitochondrial replacement. This approach targets T cell exhaustion in elderly cancer patients, improving their immune response and potential treatment outcomes.

Kamari Pharma develops TRPV3 inhibitors that repair skin damage associated with rare dermatological diseases and chronic itch. Their technology targets the TRPV3 channel, a key regulator of skin homeostasis, to address significant gaps in treatment options for patients.

Keros is a clinical-stage biopharmaceutical company developing therapeutics that modulate transforming growth factor-beta (TGF-β) signaling to address disorders linked to dysfunctional TGF-β pathways. By leveraging their expertise in TGF-β science, Keros aims to provide disease-modifying treatments for patients with these conditions.

LB Pharmaceuticals is developing LB-102, an N-Methyl amisulpride treatment aimed at addressing the symptoms of schizophrenia and other neuropsychiatric diseases. If approved by the FDA, LB-102 would be the first benzamide atypical antipsychotic available in the U.S. market for this condition.

The startup develops a proprietary B-Raf inhibitor, a small molecule that enhances the administration of epidermal growth factor receptor (EGFR) inhibitors in cancer therapy. This approach minimizes cutaneous side effects, thereby improving treatment effectiveness and the quality of life for patients undergoing EGFR therapy.

The startup develops targeted therapies for patients with rare diseases and cancer, utilizing advanced drug formulation techniques to enhance therapeutic efficacy. Their focus is on improving patient outcomes through the commercialization of specialized treatments that address unmet medical needs in oncology and rare disease sectors.

Metabomed develops targeted therapeutics that utilize proprietary drug design techniques to inhibit cancer cell growth. The company focuses on addressing the challenges of tumor resistance and heterogeneity in cancer treatment, aiming to improve patient outcomes through precision medicine.

Pact Pharma develops personalized adoptive T cell therapies that target and eliminate solid tumors by harnessing the body's immune system. Their approach addresses the limitations of conventional cancer treatments by providing tailored therapies that enhance patient-specific immune responses against tumor cells.

Precirix is developing precision radiopharmaceuticals that utilize camelid single-domain antibodies labeled with radiometals to target Fibroblast Activation Protein (FAP) in cancer treatment. This approach aims to provide a first-in-class alpha-emitting targeted radiotherapy for a broad range of tumors, addressing the need for more effective cancer therapies.